RESUMO

OBJECTIVE: To evaluate the association between subclinical hypothyroidism with early menopause, premature menopause, and last menstrual bleeding before the natural age of menopause. METHODS: This was a cross-sectional study conducted in 643 postmenopausal women aged 40-69 years. Groups were formed according to last menstrual episode: ≥45 [Natural age at menopause], 40-44 and [Early menopause], <40 [Premature menopause], and <45 [last menstrual episode before the natural age of menopause]. The Zulewski scale was applied to identify manifestations related to hypothyroidism and subclinical hypothyroidism, diagnosed with a serum TSH > 4.5 µIU/mL plus T4-free between 0.7 and 1.9 ng/dL. RESULTS: It was found that 24.4% had the last menstrual episode before the natural age of menopause, 18.6% had early menopause, and 5.7% had premature menopause. Subclinical hypothyroidism was diagnosed in 4.5% of patients. Among women with subclinical hypothyroidism, there was a higher frequency of early menopause, premature menopause, and last menstrual episode before the natural age of menopause, than in women without subclinical hypothyroidism (p < 0.05). Paresthesia (50%) and dry skin (40.7%) were the most reported hypothyroidism-related manifestations. Early menopause, premature menopause, and last menstrual episode before the natural age of menopause were associated with subclinical hypothyroidism, OR: 3.37 [95% CI: 1.40-8.10], OR: 4.31 [95% CI: 1.24-14.97], and OR: 3.57 [95% CI: 1.57-8.10], respectively. CONCLUSIONS: The last menstrual episode before the natural age of menopause, early menopause, and premature menopause were significantly associated with a higher chance of subclinical hypothyroidism.

Assuntos

RESUMO

Introducción: las mujeres con mutación BRCA1/2 (mBRCA) tienen un riesgo aumentado de desarrollar cáncer de mama (CM) y ovario (CO). La salpingo-oforectomía bilateral (SOB) se asocia con la reducción del riesgo del 80% para CO y un 50% para CM. Se recomienda realizarla entre los 35 y 40 años. Como consecuencia se produce una menopausia prematura, con un impacto negativo sobre la calidad de vida por la presencia de síntomas climatéricos, aumento del riesgo de enfermedad cardiovascular, osteoporosis y riesgo de alteración cognitiva. La terapia hormonal (THM) es el tratamiento más eficaz para la prevención de estos síntomas. Estado del arte: distintos estudios han demostrado un mayor riesgo de CM en mujeres posmenopáusicas que reciben THM en particular con terapia combinada, estrógeno + progesterona (E+P). Según el metanálisis de Marchetti y cols., en las mujeres portadoras de mBRCA que recibieron THM, no hubo diferencias en el riesgo de CM comparando E solo con E+P. En el estudio de Kotsopoulos, incluso se encontró un posible efecto protector en aquellas que usaron E solo. Otro estudio en portadoras sanas demostró que, en las mujeres menores de 45 años al momento de la SOB, la THM no afectó las tasas de CM. Sin embargo, en las mujeres mayores de 45 años, las tasas de CM fueron más altas. Como el esquema de E+P se asocia con un mayor riesgo relativo (RR) de CM, las dosis de progestágenos utilizados se deberían limitar, eligiendo derivados naturales de progesterona, de uso intermitente para disminuir la exposición sistémica. Según diferentes guías internacionales, a las portadoras de mBRCA sanas que se someten a una SOB se les debe ofrecer THM hasta la edad promedio de la menopausia. Conclusión: la menopausia prematura disminuye la expectativa de vida; es por ello que una de las herramientas para mejorar y prevenir el deterioro de la calidad de vida es la THM. El uso de THM a corto plazo parece seguro para las mujeres portadoras de mBRCA que se someten a una SOB antes de los 45 años, al no contrarrestar la reducción del riesgo de CM obtenida gracias a la cirugía. (AU)

Introduction: women with BRCA1/2 (mBRCA) mutation have an increased risk of developing breast (BC) and ovarian (OC) cancer. Bilateral salpingo-oophorectomy (BSO) is associated with an 80% risk reduction for OC and 50% for BC. The recommended age for this procedure is 35 to 40 years. The consequence is premature menopause, which hurts the quality of life due to the presence of climacteric symptoms, increased risk of cardiovascular disease, osteoporosis, and a higher risk of cognitive impairment. Hormone therapy (MHT) is the most effective treatment for preventing these symptoms. State of the art: different studies have shown an increased risk of BC in postmenopausal women receiving MHT, particularly with combined therapy, estrogen + progesterone (E+P). According to the meta-analysis by Marchetti et al., in women carrying mBRCA who received MHT, there was no difference in the risk of BC compared to E alone with E+P. In the Kostopoulos study, there was also a possible protective effect in those who used E alone. Another study in healthy carriers showed that in women younger than 45 years at the time of BSO, MHT did not affect BC rates. However, in women older than 45 years, BC rates were higher. As the E+P scheme is associated with a higher RR of BC, the doses of progestogens should be limited, choosing natural progesterone byproducts of intermittent use to decrease systemic exposure. According to various international guidelines, healthy mBRCA carriers undergoing BSO should be offered MHT until the average age of menopause. Conclusion: premature menopause decreases life expectancy, which is why one of the tools to improve and prevent deterioration of quality of life is MHT. Short-term use of MHT appears safe for women with mBRCA who undergo BSO before age 45 as it does not counteract the reduction in the risk of MC obtained by surgery. (AU)

Assuntos

RESUMO

Esse estudo objetivou avaliar o efeito da ooforectomia sob os parâmetros histomorfométricos dos cardiomiócitos e quantificação de colágeno em ratas Wistar. Vinte ratas foram utilizadas e separadas em dois grupos: GI - ooforectomizada e GII - sham-ooforectomizada. Após a recuperação anestésica os animais foram acomodados em gaiolas e separados nas condições de ciclo claro/escuro 12/12h por um período de 6 meses. Passado o período experimental, os animais foram anestesiados, o coração retirado e mergulhado em formaldeído a 10%. Os fragmentos dos ventrículos foram submetidos ao processamento histológico e corados com hematoxilina e eosina. As análises histomorfométricas (área celular e área e volume nuclear) foram realizadas pelo microscópio de luz e software ImageJ versão 1.44. Os dados foram submetidos à análise ANOVA e quando significantes, complementados pelo teste t de student (p<0,001). Observou-se uma diminuição significativa das áreas celular e nuclear dos cardiomiócitos do grupo GI quando comparado ao grupo GII, bem como a área ocupada, pelo colágeno, no músculo cardíaco foi maior em GI, quando comparado a GII. Diante disso, conclui-se que as alterações observadas nos cardiomiócitos do grupo GI, sugerem uma maior atividade apoptótica nesse grupo, devido à diminuição dos níveis séricos do estrógeno provocado pela ooforectomia e o aumento da área ocupada pelo colágeno, no grupo ooforectomizado, está associada ao efeito cardioprotetor do estrógeno.

This study aimed to evaluate the effect of oophorectomy on the morphometric variables of cardiomyocytes and quantification collagen in Wistar rats. Twenty rats were used and divided into two groups: GI - ovariectomized and GII - sham-ovariectomized. After recovery from anesthesia the animals were housed in separate cages and under the conditions of light / dark cycle 12/12h for a period of six months. After the experimental period, the animals were anesthetized, the heart removed and immersed in 10% formaldehyde. The fragments of the ventricles were subjected to histological analysis and stained with hematoxylin and eosin. Histomorphometric analysis (cell area and nuclear area and volume) were performed by light microscopy and ImageJ software version 1.44. The data were submitted to ANOVA and when significant, complemented by Student's t test (p<0.001). There was a significant decrease in cellular and nuclear areas of the GI cardiomyocytes compared to GII and the area occupied by collagen was greater in cardiac muscle GI, when compared to GII. Therefore, it is concluded that the changes observed in the GI group cardiomyocytes, suggest a higher apoptotic activity in this group, due to decreased serum estrogen levels caused by ovariectomy and increased area occupied by collagen in oophorectomized group is associated the cardioprotective effect of estrogen.

Assuntos

RESUMO

Esse estudo objetivou avaliar o efeito da ooforectomia sob os parâmetros histomorfométricos dos cardiomiócitos e quantificação de colágeno em ratas Wistar. Vinte ratas foram utilizadas e separadas em dois grupos: GI - ooforectomizada e GII - sham-ooforectomizada. Após a recuperação anestésica os animais foram acomodados em gaiolas e separados nas condições de ciclo claro/escuro 12/12h por um período de 6 meses. Passado o período experimental, os animais foram anestesiados, o coração retirado e mergulhado em formaldeído a 10%. Os fragmentos dos ventrículos foram submetidos ao processamento histológico e corados com hematoxilina e eosina. As análises histomorfométricas (área celular e área e volume nuclear) foram realizadas pelo microscópio de luz e software ImageJ versão 1.44. Os dados foram submetidos à análise ANOVA e quando significantes, complementados pelo teste t de student (p<0,001). Observou-se uma diminuição significativa das áreas celular e nuclear dos cardiomiócitos do grupo GI quando comparado ao grupo GII, bem como a área ocupada, pelo colágeno, no músculo cardíaco foi maior em GI, quando comparado a GII. Diante disso, conclui-se que as alterações observadas nos cardiomiócitos do grupo GI, sugerem uma maior atividade apoptótica nesse grupo, devido à diminuição dos níveis séricos do estrógeno provocado pela ooforectomia e o aumento da área ocupada pelo colágeno, no grupo ooforectomizado, está associada ao efeito cardioprotetor do estrógeno.(AU)

This study aimed to evaluate the effect of oophorectomy on the morphometric variables of cardiomyocytes and quantification collagen in Wistar rats. Twenty rats were used and divided into two groups: GI - ovariectomized and GII - sham-ovariectomized. After recovery from anesthesia the animals were housed in separate cages and under the conditions of light / dark cycle 12/12h for a period of six months. After the experimental period, the animals were anesthetized, the heart removed and immersed in 10% formaldehyde. The fragments of the ventricles were subjected to histological analysis and stained with hematoxylin and eosin. Histomorphometric analysis (cell area and nuclear area and volume) were performed by light microscopy and ImageJ software version 1.44. The data were submitted to ANOVA and when significant, complemented by Student's t test (p<0.001). There was a significant decrease in cellular and nuclear areas of the GI cardiomyocytes compared to GII and the area occupied by collagen was greater in cardiac muscle GI, when compared to GII. Therefore, it is concluded that the changes observed in the GI group cardiomyocytes, suggest a higher apoptotic activity in this group, due to decreased serum estrogen levels caused by ovariectomy and increased area occupied by collagen in oophorectomized group is associated the cardioprotective effect of estrogen.(AU)

Assuntos

RESUMO

Those women who have early menopause have major cardiovascular and metabolic risk. The menopause below 40 years of age has been associated to increase in the risk of early beginning of osteoporosis, cardiovascular disease and diabetes mellitus, disorders characterized by hyperglycemia and glucose intolerance due to deficiency of insulin, decrease of the effectiveness of its action or both. The menopausal hormone therapy is the principal therapeutic tool, with the aim to contribute estrogens to suppress the clinical symptomatology and to make a favorably impact on the estrogen-dependent tissues. The existing data regarding menopausal hormone therapy in women experiencing menopause at the median age should not be extrapolated to women experiencing premature menopause.

RESUMO

É esperado um aumento global de mulheres mais velhas que irão conviver com a infecção pelo HIV e que alcançarão a menopausa durante o curso da doença, em função principalmente do aumento da sobrevida após a expansão e acesso à terapia antirretroviral combinada (TARV) e do crescente número de mulheres mais velhas sendo diagnosticadas.Artigo 1. Objetivo: Investigar a idade e as taxas de incidência de menopausa natural e menopausa natural precoce e seus preditores em uma coorte de mulheres HIV-positivo no Rio de Janeiro, Brasil. Métodos: Foram incluídas mulheres HIV-positivo, com 30 anos ou mais de idade. Menopausa foi definida como última menstruação ocorrida há mais de um ano.Modelos de riscos proporcionais de Cox foram utilizados para identificar preditores de idade da menopausa natural e menopausa natural precoce. Resultados: 667 mulheres foram incluídas. A idade mediana no início do estudo foi de 34,9 [intervalo interquartil (IQR): 30,9-40,5] anos, 507 (76%) eram pré-menopausadas e 160 (24%) alcançaram a menopausa no final do acompanhamento. A idade mediana da menopausa natural foi de 48 (IQR: 45-50) anos; 36(27%) tiveram menopausa natural precoce ( 45 anos)...

As a result of the expansion of combination antiretroviral therapy (cART)coverage leading to reduction in morbidity and mortality and an increasing number of older individuals being diagnosed with HIV infection, an increased number of HIV-infected women entering menopause is expected. Article 1. Objective: To investigate the age and incidence rates of natural and earlier natural menopause and their predictors in a cohort of HIV-infected women in Rio de Janeiro, Brazil. Methods: HIV-infected women with 30 years or older were included. Menopause was defined as having more than one year since the last menstrual period. Multivariate Cox proportional hazard regression analysis was used to identify predictors of age at natural menopause and early age at natural menopause. Results: 667 women were included, median age at baseline was 34.9 [interquartile interval (IQR): 30.9-40.5 years], 507 (76%) were premenopausal and 160 (24%) reached menopause by the end of follow-up. Median age at natural menopause was 48 (IQR: 45–50) years; 36 (27%) of them had early menopause ( 45 years)...

Assuntos

RESUMO

A Organização Mundial de Saúde (OMS) estima para 2030, 27 milhões de casos incidentes de câncer. No Brasil, segundo o Instituto Nacional do Câncer, foram estimados 518.510 casos novos de câncer para os anos de 2012 e 2013. Dessa estimativa, 52.680 correspondem ao câncer de mama (CM), com um risco estimado de 52 novos casos a cada 100.000 mulheres. O câncer de mama é um dos tipos de câncer mais comuns no mundo todo. Hoje se sabe que o tratamento para o CM pode levar ao surgimento de diferentes efeitos adversos tardios, entre eles a osteoporose. Uma das principais causas de surgimento da osteoporose é a menopausa precoce, que ocorre através da diminuição da concentração de estrogênio sérico. Este trabalho teve como objetivo avaliar os efeitos na matriz óssea induzidos pela quimioterapia, simulando um tratamento para o CM, em ratas Wistar.Ratas Wistar, com aproximadamente 3 meses de idade, foram divididas em: grupo controle e grupo que recebeu quimioterapia com poliquimioterápico docetaxel + ciclofosfamida (TC). A quimioterapia foi administrada em 4 ciclos, com intervalo de 1 semana entre eles. Os ratos foram submetidos à eutanásia 5 meses após o término do tratamento, para que os efeitos tardios pudessem ser avaliados. Vários estudos foram conduzidos: dosagem sorológica de estradiol, ensaios histológicos através de imunohistoquímica, micro-fluorescência de Raios-X, micro-tomografia computadorizada. Além de microscopia eletrônica de transmissão e varredura.Analisando os resultados obtidos em conjunto, sugere-se que a etapa inicial para o desenvolvimento da osteoporose, causada pelo poliquimioterápico TC, seja a diminuição da função ovariana. Este evento leva à diminuição da concentração de estrogênio sérico, o que causa a atrofia uterina. Concomitante a estes fatos, o TC causa redução na concentração de zinco no tecido ósseo. Estes resultados associados causam um desequilíbrio na relação osteoblastos/osteoclastos no osso...

The World Health Organization (WHO) estimates for 2030, 27 million incident cases of cancer. In Brazil, according to the National Cancer Institute, there were estimated 518,510 new cases of cancer for the years 2012 and 2013. From this estimation, 52,680 will correspond to breast cancer (BC), with an estimated risk of 52 new cases per 100,000 women. BC is one of the most common cancers worldwide. Today it is known that the treatment of the BC may lead to the emergence of different late adverse effects, including osteoporosis. One of the main causes of osteoporosis is the early menopause, which occurs with decreasing the serum estrogen concentration. This study aimed to evaluate the effects on bone matrix induced by chemotherapy , simulating a treatment for BC in Wistar rats .Wistar rats, approximately 3 months old, were divided into a control group and the group receiving polichemotherapy with docetaxel + cyclophosphamide (TC). Chemotherapy was administered in 4 cycles, with an interval of 1 week between them. The rats were euthanized 5 months after the end of treatment, so that the late effects could be evaluated. Several studies were performed: dosage of serum estradiol levels, histological tests by immunohistochemistry, micro X-ray fluorescence, micro-computed tomography and also transmission and scanning electron microscopy.Analyzing the results together, it is suggested that the initial step in the development of osteoporosis caused by multidrug TC is the reduction in the ovarian function. This event leads to decreased serum concentration of estrogen, which causes uterine atrophy. Concomitant to these facts, the TC causes a reduction in the concentration of zinc in the bone tissue. These results associated cause an imbalance in the osteoblast/osteoclast ratio in the bone tissue. The reduction in estrogen leads to decreased apoptosis of osteoclasts, while the reduction of zinc inhibits osteoblast function. This imbalance affects the bone turnover...

Assuntos